Pidotimod | CAS#121808-62-6 | immunostimulant

MedKoo Cat#: 145349 | Name: Pidotimod

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pidotimod is a synthetic dipeptide molecule with biological and immunological activity on both the adaptive and the innate immune responses. Pidotimod can improve immune responses in mice and humans, protecting hosts from infection. Pidotimod has a remarkable efficacy in the treatment of pediatric recurrent respiratory tract infection because it can effectively inhibit the infection and optimize Th1/Th2 immune function

Chemical Structure

Pidotimod

CAS#121808-62-6

Theoretical Analysis

MedKoo Cat#: 145349

Name: Pidotimod

CAS#: 121808-62-6

Chemical Formula: C9H12N2O4S

Exact Mass: 244.0518

Molecular Weight: 244.27

Elemental Analysis: C, 44.25; H, 4.95; N, 11.47; O, 26.20; S, 13.13

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Pidotimod; NSC-759841;

IUPAC/Chemical Name

(R)-3-((S)-5-oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic acid

InChi Key

UUTKICFRNVKFRG-WDSKDSINSA-N

InChi Code

1S/C9H12N2O4S/c12-7-2-1-5(10-7)8(13)11-4-16-3-6(11)9(14)15/h5-6H,1-4H2,(H,10,12)(H,14,15)/t5-,6-/m0/s1

SMILES Code

OC(=O)[C@@H]1CSCN1C(=O)[C@@H]2CCC(=O)N2

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 244.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mahashur A, Thomas PK, Mehta P, Nivangune K, Muchhala S, Jain R. Pidotimod: In-depth review of current evidence. Lung India. 2019 Sep-Oct;36(5):422-433. doi: 10.4103/lungindia.lungindia_39_19. PMID: 31464215; PMCID: PMC6710962. 2: Manti S, Parisi GF, Papale M, Leonardi S. Pidotimod in allergic diseases. Minerva Pediatr. 2020 Oct;72(5):358-363. doi: 10.23736/S0026-4946.20.05967-8. Epub 2020 Jul 29. PMID: 32731733. 3: Riboldi P, Gerosa M, Meroni PL. Pidotimod: a reappraisal. Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):255-62. doi: 10.1177/039463200902200201. PMID: 19505378. 4: Zhao N, Liu C, Zhu C, Dong X, Liu X. Pidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections. Expert Rev Anti Infect Ther. 2019 Oct;17(10):803-818. doi: 10.1080/14787210.2019.1679118. Epub 2019 Oct 24. PMID: 31603361. 5: Niu H, Wang R, Jia YT, Cai Y. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: A meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019 Feb;67:35-45. doi: 10.1016/j.intimp.2018.11.043. Epub 2018 Dec 7. PMID: 30530167. 6: Puggioni F, Alves-Correia M, Mohamed MF, Stomeo N, Mager R, Marinoni M, Racca F, Paoletti G, Varricchi G, Giorgis V, Melioli G, Canonica GW, Heffler E. Immunostimulants in respiratory diseases: focus on Pidotimod. Multidiscip Respir Med. 2019 Nov 4;14:31. doi: 10.1186/s40248-019-0195-2. PMID: 31700623; PMCID: PMC6827234. 7: Ucciferri C, Falasca K, Reale M, Tamburro M, Auricchio A, Vignale F, Vecchiet J. Pidotimod and Immunological Activation in Individuals Infected with HIV. Curr HIV Res. 2021;19(3):260-268. doi: 10.2174/1570162X18666210111102046. PMID: 33430735. 8: Zuccotti GV, Mameli C. Pidotimod: the past and the present. Ital J Pediatr. 2013 Dec 6;39:75. doi: 10.1186/1824-7288-39-75. PMID: 24314100; PMCID: PMC4028890. 9: Ding L, Luo K, Feng CG, Oehlers SH. Pidotimod increases inflammation in wounded zebrafish embryos. Fish Shellfish Immunol. 2022 Jan;120:429-433. doi: 10.1016/j.fsi.2021.12.013. Epub 2021 Dec 16. PMID: 34922016. 10: Ucciferri C, Barone M, Vecchiet J, Falasca K. Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients. Mediterr J Hematol Infect Dis. 2020 Jul 1;12(1):e2020048. doi: 10.4084/MJHID.2020.048. PMID: 32670526; PMCID: PMC7340237. 11: Ferrario BE, Garuti S, Braido F, Canonica GW. Pidotimod: the state of art. Clin Mol Allergy. 2015 May 21;13(1):8. doi: 10.1186/s12948-015-0012-1. PMID: 25999796; PMCID: PMC4440502. 12: Chiappini E, Santamaria F, Marseglia GL, Marchisio P, Galli L, Cutrera R, de Martino M, Antonini S, Becherucci P, Biasci P, Bortone B, Bottero S, Caldarelli V, Cardinale F, Gattinara GC, Ciarcià M, Ciofi D, D'Elios S, Di Mauro G, Doria M, Indinnimeo L, Lo Vecchio A, Macrì F, Mattina R, Miniello VL, Del Giudice MM, Morbin G, Motisi MA, Novelli A, Palamara AT, Panatta ML, Pasinato A, Peroni D, Perruccio K, Piacentini G, Pifferi M, Pignataro L, Sitzia E, Tersigni C, Torretta S, Trambusti I, Trippella G, Valentini D, Valentini S, Varricchio A, Verga MC, Vicini C, Zecca M, Villani A. Prevention of recurrent respiratory infections : Inter-society Consensus. Ital J Pediatr. 2021 Oct 25;47(1):211. doi: 10.1186/s13052-021-01150-0. PMID: 34696778; PMCID: PMC8543868. 13: La Mantia I, Varricchio A, Andaloro C, Ciprandi C. Pidotimod in children with infectious mononucleosis: a preliminary randomized controlled study. J Biol Regul Homeost Agents. 2020 Jul-Aug;34(4):1597-1599. doi: 10.23812/20-236-L. PMID: 33222434. 14: Li X, Li Q, Wang X, Lu M, Shen J, Meng Q. Pidotimod in the treatment of pediatric recurrent respiratory tract infection. Pak J Med Sci. 2019 Jul- Aug;35(4):981-986. doi: 10.12669/pjms.35.4.82. PMID: 31372128; PMCID: PMC6659081. 15: Wu T, Cui J, Gao J, Zhou H, Li A, Guo W. Pidotimod enhanced the anti-growth effect of cisplatin on lung cancer in mice via promoting anti-tumor immune response. Biochem Biophys Res Commun. 2020 Aug 6;528(4):678-684. doi: 10.1016/j.bbrc.2020.05.117. Epub 2020 Jun 6. PMID: 32513535. 16: Marogna M, Ciprandi G. Pidotimod as add-on therapy in patients with pollen- induced allergic rhinitis and asthma and associated respiratory infections. J Biol Regul Homeost Agents. 2021 May-Jun;35(3):1053-1058. doi: 10.23812/21-103-L. PMID: 34134476. 17: Mameli C, Pasinato A, Picca M, Bedogni G, Pisanelli S, Zuccotti GV; AX- Working Group. Pidotimod for the prevention of acute respiratory infections in healthy children entering into daycare: A double blind randomized placebo- controlled study. Pharmacol Res. 2015 Jul;97:79-83. doi: 10.1016/j.phrs.2015.04.007. Epub 2015 Apr 27. PMID: 25931316. 18: Santamaria F, Montella S, Stocchero M, Pirillo P, Bozzetto S, Giordano G, Poeta M, Baraldi E. Effects of pidotimod and bifidobacteria mixture on clinical symptoms and urinary metabolomic profile of children with recurrent respiratory infections: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2019 Oct;58:101818. doi: 10.1016/j.pupt.2019.101818. Epub 2019 Jul 11. PMID: 31302340. 19: Licari A, De Amici M, Nigrisoli S, Marseglia A, Caimmi S, Artusio L, Marseglia GL. Pidotimod may prevent recurrent respiratory infections in children. Minerva Pediatr. 2014 Oct;66(5):363-7. PMID: 25253184. 20: Hu S, Fu X, Fu A, Du W, Ji J, Li W. The regulatory peptide pidotimod facilitates M2 macrophage polarization and its function. Amino Acids. 2014 May;46(5):1177-85. doi: 10.1007/s00726-014-1676-4. Epub 2014 Jan 31. PMID: 24481486.